Network meta-analysis of food and drug administration-approved treatment options for adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder by Wingerchuk, D.M. et al.
ORIGINAL RESEARCH
Network Meta-analysis of Food and Drug
Administration-approved Treatment Options
for Adults with Aquaporin-4 Immunoglobulin
G-positive Neuromyelitis Optica Spectrum Disorder
Dean M. Wingerchuk . Ina Zhang . Adrian Kielhorn . Minying Royston .
Michael Levy . Kazuo Fujihara . Ichiro Nakashima . Imran Tanvir .
Friedemann Paul . Sean J. Pittock
Received: August 11, 2021 /Accepted: October 18, 2021
 The Author(s) 2021
ABSTRACT
Introduction: Neuromyelitis optica spectrum
disorder (NMOSD) is an autoimmune disease
defined by attacks on the central nervous sys-
tem that cause irreversible damage. Recent
approval of NMOSD therapies warrants investi-
gations of comparative efficacy to inform
treatment decisions.
Methods: A network meta-analysis (NMA) of all
U.S. Food and Drug Administration-approved
therapies (eculizumab, inebilizumab, and satral-
izumab) for adults with aquaporin-4
immunoglobulin G-positive (AQP4?) NMOSD
was conducted via a systematic literature review
(SLR) using data from randomized controlled trials
(RCTs). Database searches of MEDLINE, EMBASE,
and the Cochrane Central Register of Controlled
Trials were executed for the SLR. A fixed-effects
proportional hazards Bayesian NMA was used to
estimate relative treatment effects based on data
extracted from RCTs identified during the SLR
(search enddate: 11 September 2020). Four unique
RCTs (N-MOmentum, PREVENT, SAkuraSky, and
SAkuraStar) were identified, and data from 29
publications were extracted for analysis. Network
scenarios describing the most comparable patient
population groups (such as by treatment settings)




Results: In patients treated with a monoclonal
antibody only, eculizumab was associated with a
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lower risk of relapse compared with satralizumab
(HR 0.10, 95% CrI 0.01, 0.65) and inebilizumab
(HR 0.11, 95% CrI 0.02, 0.68). In patients treated
with monoclonal antibody with or without back-
ground immunosuppressive therapy (IST),
patients treated with eculizumab ± IST were also
less likely to relapse than patients treated with
satralizumab ± IST (HR 0.24, 95% CrI 0.06, 0.98).
Conclusion: The NMA results suggest that
complement component 5 (C5) inhibition pre-
vents NMOSD relapses more effectively than
broader mechanisms of action.
PLAIN LANGUAGE SUMMARY
Neuromyelitis optica spectrumdisorder (NMOSD)
is an autoimmune disease characterized by
inflammation that damages the brain and spinal
cord. Many patients with NMOSD produce anti-
bodies against a protein called aquaporin-4
(AQP4?). In the past two years, three drugs (ecu-
lizumab, inebilizumab, and satralizumab) have
been approved by the U.S. Food and Drug
Administration for the treatment of adults with
AQP4? NMOSD. Comparing the efficacy of these
threedrugswouldhelpphysiciansmake treatment
decisions for their patients. In the absence of
clinical trials directly comparing these threedrugs,
weconductedaBayesiannetworkmeta-analysis in
order to allow for simultaneous comparisons of
these three drugs and estimate relative treatment
effects between any pair of interventions in a
connected network. With a Bayesian methodol-
ogy, it is alsopossible to estimate theprobabilityof
being the best treatment out of all other inter-
ventions in a connected network. While all three
drugs are safe and shown to prevent relapses in
placebo-controlled trials, the resultsofouranalysis
suggests that eculizumab was themost efficacious
in preventing relapses when compared with
inebilizumab or satralizumab. These findingsmay
help to informphysicians and their patientswhen
determining the best treatment option for pre-
venting the occurrence of relapses in adults with
AQP4? NMOSD.
Keywords: Neuromyelitis optica; Aquaporin-4;
Network meta-analysis; Eculizumab; Inebilizu-
mab; Satralizumab
Key Summary Points
Why carry out this study?
Three drugs (eculizumab, inebilizumab,
and satralizumab) are currently approved
by the U.S. Food and Drug Administration
for the treatment of adults with
aquaporin-4 immunoglobulin G-positive
neuromyelitis optica spectrum disorder
(AQP4? NMOSD).
In the absenceof head-to-head clinical trials,
we conducted a systematic literature review
to identify data from randomized controlled
trials (RCTs) for eculizumab, inebilizumab,
and satralizumab and then performed an
indirect treatment comparison of their
efficacy via a fixed-effects Bayesian network
meta-analysis (NMA).
What was learned from this study?
We found 29 publications from four
unique RCTs (N-MOmentum, PREVENT,
SAkuraSky, and SAkuraStar); the only
efficacy outcome that could be evaluated
in the NMA was time-to-first relapse,
because it was the only outcome shared
across all RCTs in AQP4? NMOSD.
Hazard ratios suggest that patients on
eculizumab monotherapy were 90% and
89% less likely to relapse when compared
with patients on satralizumab or
inebilizumab monotherapy, respectively;
in all three treatment-setting scenarios
tested (combined mono- and
combination therapy, monotherapy, and
combination therapy), eculizumab had
the greatest likelihood of being the best
treatment option for delaying time-to-first
relapse in adults with AQP4? NMOSD.
Our results suggest that complement
component 5 (C5) inhibition may prevent
NMOSD relapses more effectively than
treatments with broader mechanisms of
action, such as those targeting the
interleukin-6 receptor or the B-cell surface
antigen cluster of differentiation19 (CD19).
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INTRODUCTION
Neuromyelitis optica spectrum disorder (NMOSD)
is a rare, severely disabling, comple-
ment-mediated autoimmune neuroinflamma-
tory disease of the central nervous system (CNS),
characterized by devastating and unpre-
dictable attacks (relapses) that can cause imme-
diate and irreversible damage [1, 2]. Aquaporin-4
(AQP4) immunoglobulinG-induced activation of
the complement cascade is one of the primary
drivers of pathogenesis in NMOSD [3–5]. An esti-
mated 80–90%ofNMOSDcases followa relapsing
disease course [1, 6]. Any relapse can result in the
accumulation of neurological disability, includ-
ing blindness and paralysis, which highlights the
immediate need for immunotherapies that effec-
tively prevent NMOSD relapses [7–13].
Eculizumab, the first immunosuppressive
monoclonal antibody approved by the U.S. Food
and Drug Administration (FDA) to treat adults
with AQP4 immunoglobulin (AQP4?) NMOSD,
works by inhibiting the complement component
5 (C5) protein in the terminal part of the com-
plement cascade [7, 14]. In a phase 3 randomized
controlled trial (RCT) with a placebo control
(PREVENT), eculizumab demonstrated out-
standing efficacy in preventing NMOSD relapses
in adults with AQP4? NMOSD; safety outcomes
were consistent with its use in other indications
(paroxysmalnocturnalhemoglobinuria, atypical
hemolytic uremic syndrome, and generalized
myasthenia gravis) [7, 14]. Data suggest that
interleukin 6 (IL-6) may also contribute to the
inflammation that arises in AQP4? NMOSD
[15]. Satralizumab, a monoclonal antibody
which targets the IL-6 receptor (IL-6R), has
shown efficacy in a phase 3 RCT (SAkuraSky) in
combinationwith immunosuppressive therapies
(ISTs) and as a monotherapy agent (SAkuraStar)
[16, 17]. In addition, inebilizumab, a mono-
clonal antibody that evokes antibody-dependent
cellular cytolysis by binding to the B-cell surface
antigen cluster of differentiation 19 (CD19), has
been shown to reduce the risk of relapse com-
pared with placebo in a phase 2/3 placebo-con-
trolled RCT (N-MOmentum) among patients
with NMOSD [18]. At the time of this analysis,
these three therapies had received FDA approval
for the treatment of adultswithAQP4? NMOSD.
Someof themhave also received approval for this
indication from additional regulatory agencies,
such as the European Medicines Agency and the
Pharmaceuticals and Medical Devices Agency of
Japan.
With several approved therapies from which
to choose, the need for comparative efficacy
arises. Healthcare providers consider compara-
tive efficacy to be one of the parameters when
selecting a treatment for an individual patient,
and patients want to know which drug is most
likely to keep them relapse-free. Payers and
fundholders want to consider evidence on
comparative efficacy to determine coverage,
prior authorization, and reimbursement. Head-
to-head RCTs are considered the most credible
sources of evidence to obtain insight into the
relative treatment effects of different therapies.
However, it is unrealistic to expect head-to-head
RCTs to compare all interventions of interest.
This is where a network meta-analysis (NMA)
can help. With an NMA, the trial-specific
treatment effects of several therapies can be
compared simultaneously to evaluate their rel-
ative efficacy, similar to a head-to-head RCT of
all competing treatment options [19]. To our
knowledge, no NMA has been performed to
date that compares the efficacies of all three
FDA-approved treatments in adults with
AQP4? NMOSD. The aim of this study was to
evaluate the relative efficacy of all FDA-ap-
proved treatments (eculizumab, inebilizumab,
and satralizumab) by conducting an NMA based
on published data from RCTs in adults with
AQP4? NMOSD.
METHODS
Identification and Selection of Relevant
Trials
A systematic literature review (SLR) search was
conducted on 11 September 2020, focusing on
adult patients with AQP4? NMOSD. Database
searches of MEDLINE, EMBASE, and the
Cochrane Central Register of Controlled Trials
were executed using predefined search strategies
in Ovid (Electronic Supplementary Material
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[ESM] Appendix A). After the identification of
records, titles and abstracts were screened
against the eligibility criteria (see Table 1), and
duplicates were removed; full texts of the
included records were then reviewed in a sec-
ond screening round against the same criteria
(see Table 1 and ESM Appendix B). Both rounds
of screening were performed by two indepen-
dent reviewers, with any disagreements resolved
by a third reviewer. This article is based on
previously conducted studies and does not
contain any new studies with human partici-
pants or animals performed by any of the
authors.
Data Extraction and Risk Assessment
Study quality was assessed by the Cochrane Risk
of Bias tool, which evaluated the study ran-
domization process, deviations from intended
interventions, missing outcome data, measure-
ment of outcome, and selection of reported
results. Each evaluated domain is assigned a bias
status of either ‘‘low risk,’’ ‘‘of some concern,’’ or
‘‘high risk’’ (see ESM Appendix B for additional
information on data extraction and risk
assessment).
NMA and Outcomes
A Bayesian NMA was performed to compare the
relative treatment effects between eculizumab,
inebilizumab, and satralizumab based on data
extracted from RCTs identified from our SLR
and deemed sufficiently similar. Analyses were
performed for clinically relevant subpopula-
tions based on three treatment networks (see
Fig. 1):
• Analysis 1: Combined mono- and combina-
tion therapy—patients treated with a mon-
oclonal antibody with or without
background IST (Fig. 1a).
• Analysis 2: Monotherapy—patients treated
with a monoclonal antibody only (no back-
ground IST; Fig. 1b).
• Analysis 3: Combination therapy—patients
treated with a monoclonal antibody with
background IST (Fig. 1c).
Table 1 PICOS screening criteria for the systematic lit-




-Adults with AQP4? NMOSD





Comparators Placebo or best supportive care
Any intervention of interest





Health-related quality of life:
-Disease-related disability




-European Quality of Life
5-Dimension Questionnaire
Index Score
-36-item Short Form Health
Survey
Study design RCTsa
Language Only studies published in English
were included
Time No time restriction was used
Data sources
Databases (via Ovid) EMBASE
MEDLINE
Cochrane Central Register of
Controlled Clinical Trials
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These networks were selected based on our
SLR results and an evaluation of the populations
deemed most comparable for performing an
NMA. All analyses adhered to guidance from the
International Society for Pharmacoeconomics
and Outcomes Research (ISPOR) network meta-
analysis (indirect treatment comparison) Task
Force [20].
Results of an NMA are usually expressed in
two ways: hazard ratios (HRs) and rank order
probabilities. Relative treatment effects are
expressed as HRs, which is standard for an NMA
[21]. The HR is a comparison of the number of
events in a treatment group versus the number
of events in a control group, accounting for
follow-up time. In NMAs, it is rare to find sta-
tistically significant differences. In many cases,
this is because the analysis is simply under-
powered. As an NMA is more focused on iden-
tifying potential treatment effect differences
than on hypothesis testing, a Bayesian statisti-
cal approach is typically used. This approach
simultaneously allows for the calculation of
rank order probabilities [19].
The probability that a treatment is best can
be described as the proportion of samples where
the sampled effect size for one treatment is
greater than the sampled effect size of other
treatments. The samples are taken from the
model’s posterior distribution of the relative
treatment effect estimates across all treatments
compared in a network. Similarly, it is possible
to calculate the probability of being the second-
best treatment, the third-best treatment, and so
on, up to the probability of being the worst
treatment option out of those assessed. These
probability statements can be plotted in a
‘‘rankogram’’ and offer an intuitive summary of
how treatments rank given their sampled effect
size and associated uncertainty. When evaluat-
ing HRs and rank order probabilities in tandem,
the smaller the HR (i.e., the more effective the
treatment), the more likely the treatment will
be ranked first when evaluating the probability
of being the best treatment option. This infor-
mation can help to inform clinical decision-
making based on treatment efficacy [19, 22].
In our NMA, the key efficacy outcome of
time-to-first relapse—defined as the presence or
worsening of neurologic symptoms related to
NMOSD—was evaluated using a regression
model with a contrast-based normal likelihood
for the log hazard ratio (logHR) and corre-
sponding standard error of each trial (or com-
parison) in the network. The NMA was
performed under the assumption of propor-
tional hazards. Based on the posterior distribu-
tions of the relative treatment effect estimates,
rank order probabilities were also calculated.
Time-to-first relapse (assessed by an inde-
pendent review committee) was the primary
and only reported outcome shared across all
three RCTs in adults with AQP4? NMOSD.
Additional outcomes analyzed in the RCTs
included measures such as annualized relapse
rate (ARR), Expanded Disability Status Scale
(EDSS) score, Modified Rankin Scale (mRS)
score, Hauser Ambulation Index (HAI) score,
EuroQol 5-Dimension Questionnaire (EQ-5D)
index score, and 36-Item Short Form Survey (SF-
36) score. However, these results were not
available for adults with AQP4? NMOSD in all
RCTs. Because of this, an NMA with all sec-
ondary endpoints was not feasible and would
have introduced bias into the analyses. There-







Treatment and Research in
Multiple Sclerosis
American Academy of Neurology
Annual Meeting
European Academy of Neurology
Trials in progress ClinicalTrials.gov
AQP4? aquaporin-4 immunoglobulin G-positive, FDA
U.S. Food and Drug Administration, NMA network meta-
analysis, NMOSD neuromyelitis optica spectrum disorder,
PICOS Population, Intervention, Comparison, Outcomes
and Study, RCTs randomized controlled trials
aRCTs reporting at least one efficacy outcome were
selected for inclusion. All reported efficacy outcomes were
extracted from each publication identified. Only data from
AQP4? patients were included in the NMA
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Fig. 1 Network meta-analysis design: indirect treatment
comparison of time-to-first relapse in adults with AQPQ?
NMOSD. In the SAkuraSky and PREVENT studies,
background IST, such as azathioprine, mycophenolate
mofetil, and glucocorticoids, were allowed, whereas IST
was explicitly excluded from the N-MOmentum and
SAkuraStar populations. AQPQ? aquaporin-4
immunoglobulin G-positive, IST immunosuppressant
therapy, NMOSD neuromyelitis spectrum disorder
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efficacy outcome of time-to-first relapse in
patients with AQP4? NMOSD. As such, only
data from patients with AQP4? NMOSD were
included in the NMA.
Software
The parameters of the different models were esti-
mated using a Markov chain Monte Carlo
(MCMC) method implemented in the JAGS soft-
ware package. A first series of iterations from the
JAGS sampler was discarded as ‘burn-in’ and the
inferences were based on additional iterations
using two chains. All analyses were performed
using R version 3.6.1 and JAGS version 4.3.0.
RESULTS
SLR and PRISMA Flow Chart
Four unique studies (N-MOmentum, PREVENT,
SAkuraSky, and SAkuraStar) were identified in
29 publications retrieved from the databases
during the SLR (search end date: 11 September
2020). A PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) flow
diagram summarizing this study selection pro-
cess is shown in Fig. 2. Patient and trial char-
acteristics can be found in ESM Appendices C,
D, and E. Seven additional records were identi-
fied from conference proceedings of the Euro-
pean Committee for Treatment and Research in
Multiple Sclerosis (ECTRIMS), American Acad-
emy of Neurology (AAN), and European Acad-
emy of Neurology (EAN). In total, 29
publications representing four RCTs met the
Population, Intervention, Comparison, Out-
comes, and Study (PICOS) screening criteria:
N-MOmentum (inebilizumab), PREVENT (ecu-
lizumab), SAkuraSky (satralizumab), and SAku-
raStar (satralizumab; see Table 1). Of the 29
publications, HR data were pulled from the four
primary RCTs, and the remaining 25 were
abstracts (see ESM Table S4). In all trials, active
treatment with monoclonal antibodies demon-
strated significantly favorable efficacy profiles
when compared with placebo.
Treatment Effects
Analysis 1: Combined Mono- and Combination
Therapy—Eculizumab – IST has the Highest
Likelihood of Being the Best Treatment Option
for Extending Time-to-First Relapse
The HRs for time-to-first relapse in a mixed popu-
lationofpatients onmonotherapyor combination
therapy were determined from three trials evalu-
ating eculizumab and satralizumab. The relative
treatment effect of satralizumab ± IST was
obtained by pooling the results of the SAkuraStar
(monotherapy) and SAkuraSky (combination
therapy) trials.TheHRresults indicate thatpatients
treated with eculizumab ± IST are 76% less likely
to experience a first relapse compared with satral-
izumab ± IST (HR0.24, 95%credible interval [CrI]
0.06, 0.98; Fig. 3). When calculating rank order
probabilities, eculizumab ± IST demonstrated the
highest probability (98%) of being the best treat-
ment option for delaying time-to-first relapse in
adults with AQP4? NMOSD (see Table 2).
Analysis 2: Monotherapy—Patients
on Eculizumab Monotherapy Were Less Likely
to Experience a First Relapse Compared
with Satralizumab Monotherapy
or Inebilizumab Monotherapy
Time-to-first relapse was captured by three trials
evaluating all three monoclonal antibodies of
interest. The monotherapy network was com-
posed of the N-MOmentum, PREVENT (no IST),
and SAkuraStar trials. Results showed that
patients on eculizumab monotherapy were 90%
less likely to experience a first relapse when
compared with satralizumab monotherapy
(HR 0.10, 95% CrI 0.01, 0.65) and 89% less
likely to experience a first relapse when
compared with inebilizumab monotherapy
(HR 0.11, 95% CrI 0.02, 0.68; Fig. 3). Of note,
patients on eculizumab monotherapy did not
experience a relapse during the PREVENT study.
Because it is not possible to conduct an NMA
with an HR of zero, an HR of 0.025 was imputed
using the Firth correction [23].
In addition, eculizumab monotherapy had
the highest probability (99%) of being the best
treatment option for improving time-to-first
relapse in adults with AQP4? NMOSD (Table 2).
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Fig. 2 PRISMA diagram: RCT identification and selec-
tion. CENTRAL refers to the Cochrane Central Register
of Controlled Trials. PRISMA Preferred Reporting Items
for Systematic Reviews and Meta-Analyses, RCT random-
ized controlled trial
Fig. 3 Hazard ratios for time-to-first relapse in adults with
AQP4? NMOSD. In the SAkuraSky and PREVENT
trials, background IST, such as azathioprine, mycopheno-
late mofetil, and glucocorticoids, were allowed, whereas
IST was explicitly excluded from the N-MOmentum and
SAkuraStar populations. CrI credible interval, IST
immunosuppressive therapy
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Analysis 3: Combination Therapy—
Eculizumab has the Highest Probability
of Being the Best Treatment Option for Time-
to-First Relapse When Administered
in Combination with IST
The NMA showed that treatment effects for
time-to-first relapse between eculizumab ? IST
and satralizumab ? IST were comparable
(Fig. 3). Although there was a trend towards a
better HR for eculizumab ? IST, the differences
in treatment effects were too uncertain to
determine statistically if one was more favorable
than the other (HR 0.41, 95% CrI 0.07, 2.34).
However, rank order probability analyses indi-
cated that eculizumab still had the highest
probability (84%) of being the best treatment
option for delaying time-to-first relapse in
adults with AQP4? NMOSD (Table 2).
Although additional endpoints, such as ARR,
disability, heath-related quality of life (HRQoL),
and safety outcomes were reported for the RCTs,
they could not be evaluated in our NMA with-
out introducing bias. Thus, the raw data for
these outcomes were extracted from the publi-
cations and are included in ESM Appendix F.
DISCUSSION
In the combined mono- and combination
therapynetwork, patients treatedwith eculizumab
were less likely to experience a first relapse than
patients treated with satralizumab. As a mono-
therapy, eculizumab was more efficacious than
inebilizumab or satralizumab. When combined
with IST (combination therapy network),
eculizumab may also be more efficacious com-
pared with satralizumab (84% probability), but
the relative treatment effect estimate is too
uncertain to claim a significant difference at
this time. However, given the post hoc nature of
NMAs, it may be beneficial for decision-making
to note that our study found significant differ-
ences in favor of eculizumab in two out of three
treatment comparison scenarios.
Unfortunately, analyses for ARR, disability,
and HRQoL were not performed because of a
lack of consistent outcome when reported by
AQP4? status in the RCTs [16, 17]. Safety out-
comes were also excluded from the NMA
because of a lack of standardized baseline risks
and inconsistent reporting by AQP4? status
across trials.
The comparative analysis of these treat-
ments’ efficacies is intended to assist the selec-
tion of the most appropriate therapy for an
individual patient. Although efficacy is an
essential parameter when physicians are decid-
ing on a specific treatment, additional factors
are considered as part of the decision-making
process for a chronic treatment, such as treat-
ment history, patient’s preference with regards
to the mode and frequency of the drug’s
administration, established drug’s safety profile,
and insurance coverage.
Strengths and Limitations
This is a replicable analysis to estimate relative
treatment effects between the primary compet-
ing interventions for NMOSD based on a
Table 2 Rank order probabilities of the first rank: likelihood of being the best treatment option for time-to-first relapse in
adults with AQP4? NMOSD






Eculizumab 97.63% 98.67% 84.47%
Inebilizumaba – 00.74% –
Satralizumab 02.37% 00.59% 15.53%
Placebo 0 0 0
AQP4? aquaporin-4 immunoglobulin G-positive, NMOSD neuromyelitis optica spectrum disorder
aInebilizumab only has monotherapy data and was not included in Analysis 1 or 3
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commonly accepted methodology using evi-
dence from pivotal RCTs [20]. This analysis
estimates what a true head-to-head trial
involving all these interventions would likely
have shown.
No two trials enroll identical patients. The
impact of differences in patient characteristics
on absolute results is neutralized by focusing on
the relative treatment effect, meaning the
incremental, additional benefit is calculated as
the difference between the active and the con-
trol arm. For an NMA to be deemed credible,
RCTs should be as similar as possible in terms of
relative treatment effect modifiers. The authors
believe this to be the case in this analysis,
because our evidence base includes similar
RCTs, each comparing a subset of the inter-
ventions versus placebo, and the evidence from
our SLR can be organized within a single net-
work of studies in which each has at least one
intervention group or placebo group corre-
sponding with another trial. As such, the results
of our NMA can be used to compare relative
treatment effects between interventions of
interest [27].
In our analysis, a major characteristic that
differed between studies was the presence or
absence of a background IST. By performing the
analyses stratified by monotherapy and combi-
nation therapy applications, we effectively
adjusted for this difference. Additionally, these
stratified analyses are arguably more beneficial
and relevant for clinical decision-making. For the
NMA of the mixed combined mono- and com-
bination therapy population, the relative treat-
ment effects of the SAkuraSky and SAkuraStar
trials were pooled to get a relative treatment
effect representative of this mixed population.
This NMA was conducted using data from a
limited number of studies (attempting to match
one study per drug) and, therefore, it did not
allow for any between-trial adjustment of study
characteristics, such as by means of a meta-re-
gression analysis. Another limitation of the
current analysis is that no long-term follow-up
data of the identified RCTs (i.e., extension
periods) were incorporated. The lack of a pla-
cebo arm in the long-term extension arm pre-
cludes us from calculating the relative
treatment effect because it would require sig-
nificant assumptions about the data.
Additionally, the attack or relapse definition
was not completely uniform across the studies;
for example, N-MOmentum used magnetic res-
onance imaging whereas others did not [28].
However, all three studies had independent
panels that adjudicated relapses. The entry cri-
teria also varied from study to study, as well as
the IST restrictions (i.e., number of drugs that
can be used in combination). Lastly, our anal-
yses were limited by the shorter study period of
the N-MOmentum trial relative to the other
trials. N-MOmentum had a duration of only
197 days, compared with 144 weeks for the
other trials. Differences in study duration will
bias an NMA if HRs are not constant over time.
In N-MOmentum, tests for the proportionality
of hazards were completed that indicated the
effect of treatments may be reasonably assumed
to be constant. Therefore, the shorter duration
period of this trial is likely not a strong source of
bias to our NMA.
Data from an RCT conducted to explore the
efficacy of rituximab versus placebo were
recently published (RIN-1) [24], but these data
were not included in this analysis. All studies
included in this analysis required patients to
have a history of relapses during the 12 to
24 months before study start. The RIN-1 study
did not share this requirement.
CONCLUSION
In the absence of head-to-head trials, this NMA
provides important evidence on the relative
efficacy of eculizumab compared with other
approved treatments for NMOSD. Based on
currently available RCT evidence, monotherapy
and combined mono- and combination therapy
with eculizumab are more efficacious at pre-
venting relapses than inebilizumab or satral-
izumab in the treatment of adults with
AQP4? NMOSD. These findings suggest that C5
inhibition prevents relapses more effectively
than broader mechanisms of action involving
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